Disease · MONDO_0001595

choreatic disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. choreatic disease. Diseases, record MONDO_0001595. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001595

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: choreatic disease; Open Targets
Open Targets ID: MONDO_0001595; Open Targets
Other names: Chorea, Choreic movements, Choreiform movements, Hereditary benign chorea, benign familial chorea, choreia; Open Targets
Disease Ontology: DOID:12859; Disease Ontology
MeSH: D002819; MeSH
NCI Thesaurus: C84633; NCI Thesaurus
Orphanet: ORPHA:1429; Orphanet
Highest stage of its drugs: Approval, for 2 of its 7 drugs, from DailyMed, FDA and PMDA; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DEUTETRABENAZINE	CHEMBL3137326	Small molecule	Approval	DailyMed and FDA	5	3	3	Drugs and targets
TETRABENAZINE	CHEMBL117785	Small molecule	Approval	DailyMed and PMDA	4	1	1	Drugs and targets
VALBENAZINE	CHEMBL2364639	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
AMANTADINE	CHEMBL660	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BEVANTOLOL HYDROCHLORIDE	CHEMBL2106060	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MAVOGLURANT	CHEMBL3087515	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RISPERIDONE	CHEMBL85	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets12

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC18A2	Synaptic vesicular amine transporter	3	Synaptic vesicular amine transporter inhibitor	Approval	https://conductscience.org/library/genes/6571	Drugs and targets
DRD2	D(2) dopamine receptor	1	Dopamine D2 receptor antagonist	Phase 2	https://conductscience.org/library/genes/1813	Drugs and targets
GRIN1	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor antagonist	Phase 2	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor antagonist	Phase 2	https://conductscience.org/library/genes/2903	Drugs and targets
GRIN2B	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor antagonist	Phase 2	https://conductscience.org/library/genes/2904	Drugs and targets
GRIN2C	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor antagonist	Phase 2	https://conductscience.org/library/genes/2905	Drugs and targets
GRIN2D	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor antagonist	Phase 2	https://conductscience.org/library/genes/2906	Drugs and targets
GRIN3A	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor antagonist	Phase 2	https://conductscience.org/library/genes/116443	Drugs and targets
GRIN3B	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor antagonist	Phase 2	https://conductscience.org/library/genes/116444	Drugs and targets
GRM5	Metabotropic glutamate receptor 5	1	Metabotropic glutamate receptor 5 antagonist	Phase 2	https://conductscience.org/library/genes/2915	Drugs and targets

1 to 10 of 12

See all 12 targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04102579	Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease	Phase 3	128	2023-10-11	Chorea, Huntington	VALBENAZINE	Its record names the disease	ClinicalTrials.gov
NCT01897896	Alternatives for Reducing Chorea in Huntington Disease	Phase 3	119	2019-04-16	Chorea Associated With Huntington Disease	DEUTETRABENAZINE	Its record names the disease	ClinicalTrials.gov
NCT01795859	First Time Use of SD-809 in Huntington Disease	Phase 3	90	2017-08-11	Chorea	DEUTETRABENAZINE	Its record names the disease	ClinicalTrials.gov
NCT04201834	Risperidone for the Treatment of Huntington's Disease Involuntary Movements	Phase 2	6	2025-03-21	Huntington Disease, Chorea	RISPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT04400331	Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease	Phase 3	154		Chorea, Huntington	VALBENAZINE	Its record names the disease	ClinicalTrials.gov
NCT07601516	Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China	Phase 4	50		Huntington's Disease, Chorea	DEUTETRABENAZINE	Its record names the disease	ClinicalTrials.gov
NCT01019473	Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea	Phase 2	44		Huntington's Disease, Chorea	MAVOGLURANT	Its record names the disease	ClinicalTrials.gov
NCT03575676	Efficacy and Safety of SOM3355 in Huntington's Disease Chorea	Phase 2	32		Huntington's Chorea	BEVANTOLOL HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00001930	Treatment of Huntington's Chorea With Amantadine	Phase 2	25		Chorea, Huntington's Disease	AMANTADINE	Its record names the disease	ClinicalTrials.gov
NCT06312189	Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada	Phase 3	7		Chorea, Huntington	VALBENAZINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Valbenazine vs Placebo: deaths from any cause	0 of 64	1 of 63	127	NCT04102579	Trial comparisons
Valbenazine vs Placebo: serious adverse events	1 of 64	2 of 63	127	NCT04102579	Trial comparisons
Rollover Cohort: SD-809 ER vs Switch Cohort: SD-809 ER: deaths from any cause	1 of 82	0 of 37	119	NCT01897896	Trial comparisons
Rollover Cohort: SD-809 ER vs Switch Cohort: SD-809 ER: serious adverse events	21 of 82	11 of 37	119	NCT01897896	Trial comparisons
SD-809 Tablets vs SD-809 Placebo: Number of Participants With Treatment Success at the End of Therapy Based on Clinical Global Impression of Change (CGIC)	19 of 45	6 of 45	90	NCT01795859	Trial comparisons
SD-809 Tablets vs SD-809 Placebo: Number of Participants With Treatment Success at the End of Therapy as Measured by the Patient Global Impression of Change (PGIC)	23 of 45	9 of 45	90	NCT01795859	Trial comparisons
SD-809 vs Placebo: serious adverse events	1 of 45	1 of 45	90	NCT01795859	Trial comparisons

Papers from its trials11

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37210099	RESULT	1	PubMed
39825184	DERIVED	2	PubMed
38557959	DERIVED	2	PubMed
36494329	DERIVED	1	PubMed
36242718	DERIVED	1	PubMed
32250312	DERIVED	1	PubMed
29480210	DERIVED	1	PubMed
28265459	DERIVED	2	PubMed
27380342	DERIVED	1	PubMed
25689146	DERIVED	1	PubMed

1 to 10 of 11

See all 11 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001595

GET https://conductscience.org/api/diseases/v1/MONDO_0001595/drugs

API reference For AI assistants